SCHEDULE: Wellington Management Boosts Kymera Therapeutics Stake
Beneficial Ownership Report
Wellington Management Group and its affiliates report a 7.66% beneficial ownership stake in Kymera Therapeutics, Inc. common stock.
Summary
- Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, has filed an Amendment No. 6 to Schedule 13G.
- The filing reports beneficial ownership of 5,372,061 shares of Kymera Therapeutics, Inc. common stock.
- This aggregate amount represents 7.66% of the class of securities.
- The reporting entities hold shared voting power over 4,872,818 shares and shared dispositive power over 5,372,061 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects. It indicates a significant, stable institutional holding.
Positives
- A significant institutional investor, Wellington Management, maintains a substantial stake of 7.66% in Kymera Therapeutics, indicating continued confidence in the company.
Future Outlook
NA
Industry Context
This filing reflects a routine disclosure of a significant institutional investment in a biotechnology company, common for asset managers like Wellington. It does not provide specific insights into Kymera's operational performance or industry trends beyond the fact that a major investor maintains a substantial position.
Stakeholder Impact
- Shareholders: The continued significant stake by a major institutional investor like Wellington Management may be viewed positively, signaling institutional confidence in Kymera Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 08/12/2025 | Filing date of the Schedule 13G Amendment No. 6. |
Keywords
Kymera Therapeutics, Wellington Management, Institutional Ownership, Biotechnology, Investment, Common Stock, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.